Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial

In early 2020, the FDA requested that the manufacturer of lorcaserin voluntarily withdraw the drug from the market because of a signal of increased cancer risk. The FDA concluded that the drug’s benefits don’t outweigh its risks for any identifiable patient population.